CSIMarket


Innoviva Inc   (INVA)
Other Ticker:  
 

Innoviva Inc

INVA's Fundamental analysis








Innoviva Inc 's sales fell by -35.41 % in III. Quarter 2023 from the same quarter a year ago. Ranking at No. 3487

Major Pharmaceutical Preparations industry recorded growth of revenues by 29.91 %

Innoviva Inc 's net income grew by 283.91 % in III. Quarter 2023 year on year, above company average,

More on INVA's Growth


Innoviva Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Innoviva Inc PEG ratio is at 0.03 Innoviva Inc realized cash outflow of $ -1.2per share in trailing twelve-month period.
Company
4.53
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 5.12.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.43.


More on INVA's Valuation
 
 Total Debt (Millions $) 446
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 505,617
 Net Income/Employee (TTM) $ 514,711
 Receivable Turnover (TTM) 25.77
 Tangible Book Value (Per Share $) 4.33

Innoviva Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Innoviva Inc PEG ratio is at 0.03 Innoviva Inc realized cash outflow of $ -1.2per share in trailing twelve-month period.
Company
4.53
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 5.12.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.43.

Innoviva Inc Price to Book Ratio is at 2.23 lower than Indusry Avg. of 76.27. and higher than S&P 500 Avg. of 0.01

More on INVA's Valuation

  Market Capitalization (Millions $) 1,398
  Shares Outstanding (Millions) 86
  Employees 540
  Revenues (TTM) (Millions $) 273
  Net Income (TTM) (Millions $) 278
  Cash Flow (TTM) (Millions $) -104
  Capital Exp. (TTM) (Millions $) 0
  Total Debt (Millions $) 446
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 505,617
  Net Income/Employee(TTM) $ 514,711
  Receivable Turnover Ratio (TTM) 25.77
  Tangible Book Value (Per Share $) 4.33

  Market Capitalization (Millions $) 1,398
  Shares Outstanding (Millions) 86
  Employees 540
  Revenues (TTM) (Millions $) 273
  Net Income (TTM) (Millions $) 278
  Cash Flow (TTM) (Millions $) -104
  Capital Exp. (TTM) (Millions $) 0


    INVA's Profitability Comparisons
Innoviva Inc faced margin deterioraten, primarily through cost pressure. Operating Margin fell in III. Quarter 2023 to 29.44 % from 51.96 % in I. Quarter.

Innoviva Inc net profit margin of 117.38 % is currently ranking no. 40 in Major Pharmaceutical Preparations industry, ranking no. 67 in Healthcare sector and number 433 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 8.43
  Total Debt to Equity (MRQ) 0.71
  Tangible Leverage Ratio (MRQ) 1.29
  Asset Turnover Ratio (TTM) 0.22
  Inventory Turnover Ratio (TTM) 0.47



Innoviva Inc faced margin deterioraten, primarily through cost pressure. Operating Margin fell in III. Quarter 2023 to 29.44 % from 51.96 % in I. Quarter.

Innoviva Inc net profit margin of 117.38 % is currently ranking no. 40 in Major Pharmaceutical Preparations industry, ranking no. 67 in Healthcare sector and number 433 in S&P 500.

More on INVA's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com